Camp4 Therapeutics Corp
CAMP4 Therapeutics Corporation (Nasdaq: CAMP) is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics designed to increase gene expression and restore protein levels in genetic diseases. Its proprietary RAP Platform maps regulatory RNAs that control gene expression and uses that information… From the company’s description.
In fiscal 2025, Camp4 Therapeutics Corp reported revenue of $3.50M, up 436.5% from fiscal 2024, and a net loss of $80.40M. Operations used $29.55M in cash. Over the twelve months to Sep 30, 2026, revenue was $5.32M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Camp4 Therapeutics Corp does
In the company’s own words
CAMP4 Therapeutics Corporation (Nasdaq: CAMP) is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics designed to increase gene expression and restore protein levels in genetic diseases. Its proprietary RAP Platform maps regulatory RNAs that control gene expression and uses that information to design antisense oligonucleotide candidates. The lead candidate, CMP-002, is an intrathecally delivered therapy for SYNGAP1-related disorder, a developmental and epileptic encephalopathy; the company is also advancing discovery programs for other developmental and epileptic encephalopathies. CMP-001, developed for urea-cycle disorders, has completed a Phase 1 trial in healthy volunteers, and the company is pursuing partnership opportunities for its further development. CAMP4 operates as a single business focused on drug discovery and development rather than reporting operating segments. Its 2025 collaboration with GSK covers research and development of RNA-targeting candidates for neurodegenerative and kidney disease targets, with GSK responsible for subsequent development and commercialization of licensed products. CAMP4 was founded on research in transcription regulation and has licensed relevant patent rights from the Whitehead Institute. Its website is https://www.camp4tx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- WATERTOWN, MA
- Fiscal year end
- December
- CIK
- 1736730
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Camp4 Therapeutics Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Camp4 Therapeutics Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Camp4 Therapeutics Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Camp4 Therapeutics Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Camp4 Therapeutics Corp's last four quarterly filings that the numbers alone won't show?”